REVIEW
|
doi:10.20944/preprints202112.0282.v1
Subject:
Medicine And Pharmacology,
Oncology And Oncogenics
Keywords:
Acalabrutinib; Bruton’s tyrosine kinase; BTK; CLL; Covalent inhibitors; COVID-19; Ibrutinib; Non-covalent inhibitors; Fenebrutinib; MK1026; Pirtobrutinib; Spebrutinib; Tirabrutinib; Zanubrutinib
Online: 16 December 2021 (16:13:54 CET)